REAL AD-Validation of a realistic screening approach for early Alzheimer's disease.
Alzheimer's disease
blood‐based biomarkers
digital biomarker
primary care
screening
Journal
Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978
Informations de publication
Date de publication:
23 Sep 2024
23 Sep 2024
Historique:
revised:
31
07
2024
received:
19
05
2024
accepted:
02
08
2024
medline:
23
9
2024
pubmed:
23
9
2024
entrez:
23
9
2024
Statut:
aheadofprint
Résumé
Early diagnosis is crucial to treatment success. This is especially relevant for Alzheimer's disease (AD), with its protracted preclinical phase. Most health care systems do not have the resources to conduct large-scale AD screenings in middle-aged individuals in need of novel AD treatment options and early, accurate diagnosis. Recent developments in blood-based biomarkers and remote cognitive testing offer novel, cost-effective, and scalable methods to detect cognitive and biomarker changes that may indicate early AD. In research cohorts, promising results have been reported, but these modalities have not been validated in population-based settings. The validation of a realistic screening approach for early Alzheimer's disease (REAL AD) study aims to validate the diagnostic and prognostic performance of the combined use of blood-based biomarkers and remote cognitive testing as a screening approach for early AD employing an existing health care infrastructure (the Swedish Västra Götaland Region Primary Healthcare). REAL AD aims to provide a concrete, individualized diagnostic framework, which could significantly improve AD prognosis. HIGHLIGHTS: In Sweden, most Alzheimer's disease (AD) diagnoses are made in primary care, where access to AD biomarkers is almost non-existent. Most health care systems have limited resources for the screening of middle-aged adults for early evidence of AD pathology. Blood-based biomarkers and remote cognitive testing offer novel, cost-effective, and scalable methods for detecting cognitive and biomarker changes that may indicate early AD. The REAL AD study aims to validate the diagnostic and prognostic performance of blood-based biomarkers and remote cognitive testing as a screening approach for early AD in an existing primary health care infrastructure in the Västra Götaland Region in Sweden. Studies such as REAL AD will play a vital role in helping to move the field toward concrete implementation of biomarkers in AD diagnostic workup at all care levels, eventually providing more comprehensive treatments options for the large and growing AD population, and for those at risk.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Swedish state
ID : ALFGBG-965923
Organisme : Swedish state
ID : ALFGBG-81392
Organisme : Swedish state
ID : ALF GBG-771071
Organisme : the Alzheimerfonden
ID : AF-842471
Organisme : the Alzheimerfonden
ID : AF-737641
Organisme : the Alzheimerfonden
ID : AF-929959
Organisme : the Alzheimerfonden
ID : AF-939825
Organisme : Swedish Research Council
ID : 2019-02075
Organisme : Swedish Research Council
ID : 2019-02075_15
Organisme : Stiftelsen Psykiatriska Forskningsfonden
Organisme : Stiftelsen Demensfonden
Organisme : Stiftelsen Hjalmar Svenssons Forskningsfond; and Stiftelsen Wilhelm och Martina Lundgrens vetenskapsfond
Organisme : European Union's Horizon Europe research and innovation programme
ID : 101053962
Organisme : Swedish State Support for Clinical Research
ID : #ALFGBG-71320
Organisme : Alzheimer's Drug Discovery Foundation
ID : #201809-2016862
Organisme : AD Strategic Fund and the Alzheimer's Association
ID : #ADSF-21-831376-C
Organisme : AD Strategic Fund and the Alzheimer's Association
ID : #ADSF-21-831381-C
Organisme : AD Strategic Fund and the Alzheimer's Association
ID : #ADSF-21-831377-C
Organisme : AD Strategic Fund and the Alzheimer's Association
ID : #ADSF-24-1284328-C
Organisme : Bluefield Project
Organisme : Cure Alzheimer's Fund
Organisme : Olav Thon Foundation
Organisme : Erling-Persson Family Foundation
Organisme : Familjen Rönströms Stiftelse
Organisme : Stiftelsen för Gamla Tjänarinnor
Organisme : Hjärnfonden, Sweden
ID : #FO2022-0270
Organisme : Marie Skłodowska-Curie
ID : 860197
Organisme : European Union Joint Programme - Neurodegenerative Disease Research
ID : JPND2021-00694
Organisme : UK Dementia Research Institute at UCL
ID : UKDRI-1003
Organisme : Alzheimer's Association
ID : AARF-22-972252
Pays : United States
Organisme : Gun & Bertil Stohnes Stiftelse
Organisme : European Union Joint Program for Neurodegenerative Disorders
ID : JPND2019-466-236
Organisme : Alzheimer's Association 2021 Zenith
ID : ZEN-21-848495
Organisme : La Fondation Recherche Alzheimer
Organisme : Kirsten and Freddy Johansen Foundation
Organisme : Knut and Alice Wallenberg Foundation
Organisme : NIH HHS
ID : R01 AG081394-01
Pays : United States
Organisme : National Research Foundation of Korea
ID : RS-2023-00263612
Organisme : Swedish Brain Foundation
ID : FO2021-0311
Organisme : Swedish Brain Foundation
ID : FO2024-0372
Organisme : Swedish Alzheimer Foundation
ID : #AF-930351
Organisme : Swedish Alzheimer Foundation
ID : #AF-939721
Organisme : Swedish Alzheimer Foundation
ID : #AF-968270
Organisme : Swedish Alzheimer Foundation
ID : #AF-994551
Organisme : Swedish Alzheimer Foundation
ID : AF-994900
Organisme : Sahlgrenska Academy at the University of Gothenburg
Organisme : Västra Götaland Region R&D
ID : VGFOUREG-995510
Organisme : National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre
Informations de copyright
© 2024 The Author(s). Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Références
Gustavsson A, Norton N, Fast T, et al. Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimers Dement. 2023;19:658‐670.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS‐ADRDA Work Group under the auspices of department of health and human services task force on Alzheimer's Disease. Neurology. 1984;34:939‐944.
Jack CR Jr, Bennett DA, Blennow K, et al. NIA‐AA Research Framework: toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018;14:535‐562.
Jack CR Jr, Andrews JS, Beach TG, et al. Revised criteria for diagnosis and staging of Alzheimer's disease: alzheimer's Association Workgroup. Alzheimers Dement. 2024.
Dubois B, Feldman HH, Jacova C, et al. Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS‐ADRDA criteria. Lancet Neurol. 2007;6:734‐746.
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG‐2 criteria. Lancet Neurol. 2014;13:614‐629.
Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two randomized phase 3 studies of aducanumab in early Alzheimer's disease. J Prev Alzheimers Dis. 2022;9:197‐210.
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double‐blind, phase 2b proof‐of‐concept clinical trial in early Alzheimer's disease with lecanemab, an anti‐Abeta protofibril antibody. Alzheimers Res Ther. 2021;13:80.
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388:9‐21.
Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer's disease. Nature. 2016;537:50‐56.
Jagust WJ, Landau SM. Alzheimer's disease neuroimaging I. temporal dynamics of beta‐amyloid accumulation in aging and Alzheimer disease. Neurology. 2021;96:e1347‐e1357.
Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol. 2013;12:357‐367.
Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Cerebrospinal fluid levels of beta‐amyloid 1‐42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry. 2012;69:98‐106.
Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. Lancet Neurol. 2018;17:241‐250.
Boxer AL, Sperling R. Accelerating Alzheimer's therapeutic development: the past and future of clinical trials. Cell. 2023;186:4757‐4772.
Sperling RA, Donohue MC. Trial of solanezumab in preclinical Alzheimer's disease. N Engl J Med. 2023;389:1096‐1107.
Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin? Sci Transl Med. 2014;6:228fs13.
Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3‐45 Study: design of a prevention trial for Alzheimer's disease. Alzheimers Dement. 2023;19:1227‐1233.
Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27:954‐963.
(Apr2022). Gnnhwnca.
(Apr2022). Chwccua.
Ohman F, Hassenstab J, Berron D, Scholl M, Papp KV. Current advances in digital cognitive assessment for preclinical Alzheimer's disease. Alzheimers Dement (Amst). 2021;13:e12217.
Verberk IMW, Thijssen E, Koelewijn J, et al. Combination of plasma amyloid beta((1‐42/1‐40)) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. Alzheimers Res Ther. 2020;12:118.
Simren J, Leuzy A, Karikari TK, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimers Dement. 2021;17:1145‐1156.
Stockmann J, Verberk IMW, Timmesfeld N, et al. Amyloid‐beta misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Alzheimers Res Ther. 2020;12:169.
Smirnov DS, Ashton NJ, Blennow K, et al. Plasma biomarkers for Alzheimer's disease in relation to neuropathology and cognitive change. Acta Neuropathol. 2022;143:487‐503.
Moscoso A, Grothe MJ, Ashton NJ, et al. Longitudinal associations of blood phosphorylated tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol. 2021;78:396‐406.
Grothe MJ, Moscoso A, Ashton NJ, et al. Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy. Neurology. 2021;97:e1229‐e1242.
Veitch DP, Weiner MW, Miller M, et al. The Alzheimer's disease neuroimaging initiative in the era of Alzheimer's disease treatment: a review of ADNI studies from 2021 to 2022. Alzheimers Dement. 2024;20:652‐694.
Malzbender K, Barbarino P, Barkman Ferrell P, et al. Validation, deployment, and real‐world implementation of a modular toolbox for Alzheimer's disease detection and dementia risk reduction: the AD‐RIDDLE Project. J Prev Alzheimers Dis. 2024;11:329‐338.
Tate A, Suarez‐Calvet M, Ekelund M, et al. Precision medicine in neurodegeneration: the IHI‐PROMINENT project. Front Neurol. 2023;14:1175922.
Galvin JE. The quick dementia rating system (Qdrs): a rapid dementia staging tool. Alzheimers Dement (Amst). 2015;1:249‐259.
https://www.simpler4health.se
Buysse DJ, Reynolds CF, 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res. 1989;28:193‐213.
42‐52. LJAsnaepFCH.
Lovibond SH LPDASSdt‐.
Bohn MJ, Babor TF, Kranzler HR. The Alcohol Use Disorders Identification Test (AUDIT): validation of a screening instrument for use in medical settings. J Stud Alcohol. 1995;56:423‐432.
Berman AH, Bergman H, Palmstierna T, Schlyter F. Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a Swedish population sample. Eur Addict Res. 2005;11:22‐31.
John OP, Donahue EM, Kentle RL. Big Five Inventory. APA PsycTests; 1991. doi:10.1037/t07550‐000
Craig CL, Marshall AL, Sjostrom M, et al. International physical activity questionnaire: 12‐country reliability and validity. Med Sci Sports Exerc. 2003;35:1381‐1395.
Eckerstrom M, Skoogh J, Rolstad S, et al. Sahlgrenska academy self‐reported cognitive impairment questionnaire (SASCI‐Q)–a research tool discriminating between subjectively cognitively impaired patients and healthy controls. Int Psychogeriatr. 2013;25:420‐430.
Berron D, Cardenas‐Blanco A, Bittner D, et al. Higher CSF tau levels are related to hippocampal hyperactivity and object mnemonic discrimination in older adults. J Neurosci. 2019;39:8788‐8797.
Berron D, Neumann K, Maass A, et al. Age‐related functional changes in domain‐specific medial temporal lobe pathways. Neurobiol Aging. 2018;65:86‐97.
Del Giovane M, Trender WR, Balaet M, et al. Computerised cognitive assessment in patients with traumatic brain injury: an observational study of feasibility and sensitivity relative to established clinical scales. EClinicalMedicine. 2023;59:101980.
Jolly AE, Scott GT, Sharp DJ, Hampshire AH. Distinct patterns of structural damage underlie working memory and reasoning deficits after traumatic brain injury. Brain. 2020;143:1158‐1176.
Hampshire A, Trender W, Chamberlain SR, et al. Cognitive deficits in people who have recovered from COVID‐19. EClinicalMedicine. 2021;39:101044.
Hampshire A, Azor A, Atchison C, et al. Cognition and memory after Covid‐19 in a large community sample. N Engl J Med. 2024;390:806‐818.
Chong JR, Ashton NJ, Karikari TK, et al. Blood‐based high sensitivity measurements of beta‐amyloid and phosphorylated tau as biomarkers of Alzheimer's disease: a focused review on recent advances. J Neurol Neurosurg Psychiatry. 2021;92:1231‐1241.
Ashton NJ, Leuzy A, Lim YM, et al. Increased plasma neurofilament light chain concentration correlates with severity of post‐mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathol Commun. 2019;7:5.
Chatterjee P, Pedrini S, Ashton NJ, et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease. Alzheimers Dement. 2022;18:1141‐1154.
Karikari TK, Ashton NJ, Brinkmalm G, et al. Blood phospho‐tau in Alzheimer disease: analysis, interpretation, and clinical utility. Nat Rev Neurol. 2022;18:400‐418.
Brum WS, Ashton NJ, Simren J, et al. Biological variation estimates of Alzheimer's disease plasma biomarkers in healthy individuals. Alzheimers Dement. 2024;20:1284‐1297.
Benedet AL, Brum WS, Hansson O, et al. The accuracy and robustness of plasma biomarker models for amyloid PET positivity. Alzheimers Res Ther. 2022;14:26.
Brum WS, Docherty KF, Ashton NJ, et al. Effect of neprilysin inhibition on Alzheimer disease plasma biomarkers: a secondary analysis of a randomized clinical trial. JAMA Neurol. 2024;81:197‐200.
Van Hulle C, Jonaitis EM, Betthauser TJ, et al. An examination of a novel multipanel of CSF biomarkers in the Alzheimer's disease clinical and pathological continuum. Alzheimers Dement. 2021;17:431‐445.
Donohue MC, Sperling RA, Salmon DP, et al. The preclinical Alzheimer cognitive composite: measuring amyloid‐related decline. JAMA Neurol. 2014;71:961‐970.
Mormino EC, Papp KV, Rentz DM, et al. Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated amyloid beta. Alzheimers Dement. 2017;13:1004‐1012.
Bransby L, Lim YY, Ames D, et al. Sensitivity of a Preclinical Alzheimer's Cognitive Composite (PACC) to amyloid beta load in preclinical Alzheimer's disease. J Clin Exp Neuropsychol. 2019;41:591‐600.
Sikkes SA, Knol DL, Pijnenburg YA, de Lange‐de Klerk ES, Uitdehaag BM, Scheltens P. Validation of the Amsterdam IADL Questionnaire(c), a new tool to measure instrumental activities of daily living in dementia. Neuroepidemiology. 2013;41:35‐41.
Leuzy A, Smith R, Ossenkoppele R, et al. Diagnostic Performance of RO948 F 18 tau positron emission tomography in the differentiation of Alzheimer disease from other neurodegenerative disorders. JAMA Neurol. 2020;77:955‐965.
Braak H, Braak E. Neuropathological stageing of Alzheimer‐related changes. Acta Neuropathol. 1991;82:239‐259.
Berron D, Ziegler G, Vieweg P, et al. Feasibility of digital memory assessments in an unsupervised and remote study setting. Front Digit Health. 2022;4:892997.
Ohman F, Berron D, Papp KV, et al. Unsupervised mobile app‐based cognitive testing in a population‐based study of older adults born 1944. Front Digit Health. 2022;4:933265.
Lesoil C, Bombois S, Guinebretiere O, et al. Validation study of “Sante‐Cerveau”, a digital tool for early cognitive changes identification. Alzheimers Res Ther. 2023;15:70.
Liang Y, Pertzov Y, Nicholas JM, et al. Visual short‐term memory binding deficit in familial Alzheimer's disease. Cortex. 2016;78:150‐164.
Jutten RJ, Papp KV, Hendrix S, et al. Why a clinical trial is as good as its outcome measure: a framework for the selection and use of cognitive outcome measures for clinical trials of Alzheimer's disease. Alzheimers Dement. 2023;19:708‐720.
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER‐ALZ 2 randomized clinical trial. JAMA. 2023;330:512‐527.
Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood‐based biomarkers for Alzheimer's disease: towards clinical implementation. Lancet Neurol. 2022;21:66‐77.
Hansson O, Edelmayer RM, Boxer AL, et al. The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease. Alzheimers Dement. 2022;18:2669‐2686.
Palmqvist S, Tideman P, Cullen N, et al. Prediction of future Alzheimer's disease dementia using plasma phospho‐tau combined with other accessible measures. Nat Med. 2021;27:1034‐1042.
Schindler SE, Galasko D, Pereira AC, et al. Acceptable performance of blood biomarker tests of amyloid pathology—recommendations from the Global CEO Initiative on Alzheimer's disease. Nat Rev Neurol. 2024;20:426‐439.
Cummings J, Feldman HH, Scheltens P. The “rights” of precision drug development for Alzheimer's disease. Alzheimers Res Ther. 2019;11:76.